License and Sponsored Research Agreements - Additional Information (Details) - USD ($)		1 Months Ended			3 Months Ended		9 Months Ended
	Jul. 01, 2021	Sep. 30, 2022	Nov. 30, 2020	Aug. 31, 2019	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and development expenses					$ 7,423,000	$ 2,925,000	$ 19,642,000	$ 7,413,000
Temple License Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Agreement effective date				Aug. 12, 2019
Assignment fees				$ 100,000
Development regulatory and commercial milestone payment				$ 1,250,000
Royalty percentage				50.00%
Agreement expiration description							The Temple License Agreement will remain effective until (i) the expiration date of the last-to-expire patents covered under the License Agreement (currently expected to occur in 2041); (ii) the termination by Temple upon (a) an uncured breach by the Company, with a 60-day notification period, (b) the Company’s filing of a voluntary petition in bankruptcy or related proceeding, providing such petition is not dismissed within 90 days after the filing thereof, (c) a failure by the Company to meet certain milestones set forth in the Licensed Agreement, or (d) non-payment of undisputed monies due to Temple, with a 30-day notification period. Additionally, the Company may terminate the entire agreement or with respect to an individual patent or patent application, if desired, subject a 90-day notification period.
Preclinical term	3 years
Sponsored research agreement fund	$ 900,000
Sponsored research agreement fund, net	$ 5,300,000
Sponsor research agreement funded and/or incurred from inception		$ 2,200,000			2,200,000		$ 2,200,000
Research and development expenses					400,000	$ 500,000	800,000	$ 700,000
Temple License Agreement [Member] \| Minimum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Annual administrative fee				$ 20,000
Temple License Agreement [Member] \| Common Stock [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Common stock, shares issued				97,879
Additional shares issued upon closing of Series A convertible preferred stock			9,130
Utah License Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Preclinical term		5 years
Sponsored research agreement fund		$ 3,500,000			3,500,000		3,500,000
Research and development expenses					$ 200,000		$ 200,000

Renovacor, Inc. 10-Q